Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty

NCT07537036 | Recruiting

• 1 other identifier: 36264PR131011044/3/26
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.

Conditions

Analgesic Efficacy; Quadro-Iliac Plane Block; Erector Spinae Plane Block; Total Hip Arthroplasty

Outcome Measures

Primary Outcomes (1)

• Time to the first rescue analgesia

  Time to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.

  24 hours postoperatively

Secondary Outcomes (4)

• Total morphine consumption

  24 hours postoperatively

• Degree of pain

  24 hours postoperatively

• Quality of recovery

  24 hours postoperatively

• Incidence of adverse events

  24 hours postoperatively

Study Arms (2)

QIPB group

EXPERIMENTAL

Patients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%.

Other: Quadro-iliac plane block

ESPB group

EXPERIMENTAL

Patients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%.

Other: Erector spinae plane block

Interventions

Quadro-iliac plane block OTHER

Patients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%.

QIPB group

Erector spinae plane block OTHER

Patients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%.

ESPB group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years.
• Both sexes.
• American Society of Anesthesiology (ASA) physical status I-III.
• Undergoing total hip arthroplasty (THA) under spinal anesthesia.

You may not qualify if:

• History of allergies to local anesthetics.
• Opioid dependency.
• Body mass index (BMI) \> 35 kg/m2.
• Cognitive impairment.
• Bleeding or coagulation disorders.
• Psychiatric and neurological disorder.
• Local infection at the site of injection.
• Severe heart, lung, liver, and renal dysfunction.
• Emergency surgery.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

Central Study Contacts

Mohammed S Elsharkawy, MD

CONTACT

00201148207870; mselsharkawy@med.tanta.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: April 11, 2026
• First Posted: April 17, 2026
• Study Start: April 18, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: April 21, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)